Search research articles
Contact Us
Filters
Showing results (81-90 of 105) with videos related to
Page
of 11
Sort By:
Genes & Development
|
July 13, 2017
PRKCI promotes immune suppression in ovarian cancer
Sharmistha Sarkar, Christopher A Bristow, Prasenjit Dey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Nature Communications
|
December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
Gynecologic Oncology
|
June 8, 2026
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004
Xiaodan Tang, Helen Huang, John D Peipert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
JAMA Oncology
|
July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Min Liu, Nabihah Tayob, Livius Penter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 105) with videos related to
Sort By:
Page
of 11
Genes & Development
|
July 13, 2017
PRKCI promotes immune suppression in ovarian cancer
Sharmistha Sarkar, Christopher A Bristow, Prasenjit Dey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Nature Communications
|
December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
Gynecologic Oncology
|
June 8, 2026
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004
Xiaodan Tang, Helen Huang, John D Peipert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
JAMA Oncology
|
July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Min Liu, Nabihah Tayob, Livius Penter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Page
of 11